Literature DB >> 35895166

Nicorandil Suppresses Ischemia-Induced Norepinephrine Release and Ventricular Arrhythmias in Hypertrophic Hearts.

Miyuki Kobara1, Toshihiro Amano2, Hiroe Toba2, Tetsuo Nakata2.   

Abstract

PURPOSE: Ventricular arrhythmias (VAs) are a common cause of sudden death in acute myocardial infarction (MI), for which hypertension is a major risk factor. Nicorandil opens ATP-sensitive potassium (KATP) channels, which are expressed by nerve terminals and cardiomyocytes and regulate the release of norepinephrine (NE). However, the effects of nicorandil on ischemic NE release in cardiac tissue remain unclear. Therefore, we herein investigated whether nicorandil suppressed interstitial NE concentrations and VAs during acute MI in pressure overload-induced hypertrophic hearts.
METHODS: Rats were divided into two groups: an abdominal aortic constriction (AAC) group and sham-operated (Sham) group. Four weeks after constriction, cardiac geometry and functions were examined using echocardiography and hemodynamic analyses. Myocardial ischemia was induced by coronary artery occlusion for 100 min with or without the administration of nicorandil. VAs were assessed by electrocardiography, and NE concentrations in the ischemic region were measured using a micro-dialysis method.
RESULTS: AAC induced left ventricular hypertrophy with diastolic dysfunction. VAs markedly increased in the early phase (0-20 min) of ischemia in both groups and were more frequent in the AAC group. Cardiac interstitial NE concentrations were higher in the AAC group before ischemia and significantly increased during ischemia in both groups. Nicorandil significantly suppressed ischemia-induced VAs and NE increases in the AAC group.
CONCLUSION: Ischemia-induced VAs were more frequent in hypertrophic hearts and associated with high interstitial concentrations of NE. The attenuation of ischemia-induced increases in NE through neuronal KATP opening by nicorandil may suppress ischemia-induced VAs in hypertrophic hearts.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiac hypertrophy; Nicorandil; Norepinephrine; Ventricular arrhythmia

Year:  2022        PMID: 35895166     DOI: 10.1007/s10557-022-07369-1

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.947


  5 in total

1.  In vivo monitoring of myocardial interstitial norepinephrine by dialysis technique.

Authors:  T Akiyama; T Yamazaki; I Ninomiya
Journal:  Am J Physiol       Date:  1991-11

2.  [Contractility and elevated catecholamine sensitivity of pressure-produced hypertrophied heart].

Authors:  K O Bischoff; W Meesmann; U Wild
Journal:  Z Kardiol       Date:  1974-11

3.  Ischemic preconditioning and diazoxide limit mitochondrial Ca overload during ischemia/reperfusion: Role of reactive oxygen species.

Authors:  Matt Eaton; Lisa A Hernandez; Saul Schaefer
Journal:  Exp Clin Cardiol       Date:  2005

Review 4.  [Myocardial hypertrophy and arterial hypertension].

Authors:  G Trevi; I Sheiban; R Gorni
Journal:  G Ital Cardiol       Date:  1995-10

5.  Effect of nicorandil treatment adjunctive to percutaneous coronary intervention in patients with acute myocardial infarction: a systematic review and meta-analysis.

Authors:  Jin Zhou; Jing Xu; Aijuan Cheng; Peng Li; Bingwei Chen; Shan Sun
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.